Dravet Syndrome Market Research Report– Forecast till 2027

Dravet syndrome market research information: by type of seizures (myoclonic, partial, absence seizures), diagnosis (MRI, EEG, SCN1A testing), treatment (seizure medications, ketogenic diet, vagus nerve stimulation), end-user - forecast till 2027

ID: MRFR/Pharma/4062-HCR | February 2021 | Region: Global | 85 pages

Dravet Syndrome Market Scenario:


Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.


It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the dravet syndrome market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.


Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the dravet syndrome market.


Despite these drivers, there are some issues associated with dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the dravet syndrome market.


It is estimated that the dravet syndrome market is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.


Research Methodology


 Dravet syndrome


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience:



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities


Key Players:


Some of key the players in the dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.


Segmentation:


The Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.


On the basis of the type of seizures, the dravet syndrome market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.


On the basis of the diagnosis, the dravet syndrome market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.


On the basis of the treatment & management, the dravet syndrome market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.


On the basis of the end-user, the dravet syndrome market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.


Regional Analysis:


The Americas dominate the Dravet syndrome market owing to the presence of a large number of leading market players, rising development of new drugs, and high healthcare expenditure. Various US-based pharmaceutical companies such as Zogenix, Inc., Insys Therapeutics, Inc., and OPKO Health, Inc. are continuously putting efforts to come up with novel drugs to control Dravet syndrome and related complications.


Europe holds the second position in the Dravet syndrome market. It is expected that the support provided by the government authorities for research & development and initiatives taken to improve the reimbursement policies in healthcare is likely to drive the European market.


Asia Pacific is the fastest growing Dravet syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure in Australia was USD 170.4 billion, which is recorded to be 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.5% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type of seizures, Diagnosis, Treatment & Management, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others
  Key Market Opportunities

  • Rising healthcare expenditure in the developed countries
  • Improving regulatory framework
  • Increasing adoption rate
  • Rising funding and reimbursement policies
  •   Key Market Drivers

  • Development of new drugs and therapies
  • Rising R&D expenditure


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Dravet syndrome market is projected to grow at approximately 8.5% CAGR during the assessment period (2020-2027).

    Increasing government assistance, rising healthcare expenditures, improving regulatory framework, and increasing adoption rate are the major tailwinds pushing the growth of the Dravet syndrome market.

    Side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system are major growth impeders for the Dravet syndrome market.

    North America holds the largest share in the Dravet syndrome market, followed by Europe and the Asia Pacific, respectively.

    Biscayne Neurotherapeutics, Biocodex, Cyberonics, Inc., GW Pharmaceuticals, plc, Epygenix Therapeutics, Inc., Insys Therapeutics, Inc., Ovid Therapeutics, OPKO Health Inc., PTC Therapeutics, Takeda Pharmaceutical Company Limited, Sage Therapeutics, Thermo Fisher Life Technologies, Zogenix, Inc, and Xenon Pharmaceuticals, are some of the top players operating in the Dravet syndrome market.

    Table of Contents:


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Dravet Syndrome Market, by Diagnosis

    6.1 Introduction

    6.2 Magnetic Resonance Imaging (MRI)

    6.2.1 Market Estimates & Forecast, 2020 – 2027

    6.3 Electroencephalography (EEG)

    6.3.1 Market Estimates & Forecast, 2020 – 2027

    6.4 SCN1A Testing

    6.4.1 Market Estimates & Forecast, 2020 – 2027

    6.5 Others

    6.5.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Dravet Syndrome Market, by Type of Seizures

    7.1 Introduction

    7.2 Myoclonic Seizures

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Atonic Seizures

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Partial Seizures

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    7.5 Absence Seizures

    7.5.1 Market Estimates & Forecast, 2020 – 2027

    7.6 Tonic Clonic Seizures

    7.6.1 Market Estimates & Forecast, 2020 – 2027

    7.7 Photosensitive Seizures

    7.7.1 Market Estimates & Forecast, 2020 – 2027

    7.8 Others

    7.8.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Dravet Syndrome Market, by Treatment & Management

    8.1 Introduction

    8.2 Seizure Medications

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Ketogenic Diet

    8.3.1 Market Estimates & Forecast, 2020 – 2027

    8.4 Vagus Nerve Stimulation (VNS)

    8.4.1 Market Estimates & Forecast, 2020 – 2027

    8.5 Others

    8.5.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 9. Global Dravet Syndrome Market, by End User

    9.1 Introduction

    9.2 Pharmaceutical Companies

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Hospitals

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Diagnostic Laboratories

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    9.5 Academic and Research Institutes

    9.5.1 Market Estimates & Forecast, 2020 – 2027

    9.6 Academic and Research Institutes

    9.6.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 10. Global Dravet Syndrome Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Biocodex

    12.1.1 Company Overview

    12.1.2 Diagnosis of Causative Agents Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Biscayne Neurotherapeutics

    12.2.1 Company Overview

    12.2.2 Diagnosis of Causative Agents Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 GW Pharmaceuticals, plc

    12.3.1 Company Overview

    12.3.2 Diagnosis of Causative Agents Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Zogenix, Inc

    12.4.1 Company Overview

    12.4.2 Diagnosis of Causative Agents/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

    12.5.1 Company Overview

    12.5.2 Diagnosis of Causative Agents Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 OPKO HEALTH INC.

    12.6.1 Company Overview

    12.6.2 Diagnosis of Causative Agents Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 PTC Therapeutics

    12.7.1 Overview

    12.7.2 Diagnosis of Causative Agents Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Dravet Syndrome Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Dravet Syndrome Industry Synopsis, 2020 – 2027

    Table 2 Dravet Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Dravet Syndrome Market by Region, 2020 – 2027, (USD Million)

    Table 4 Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 5 Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 6 Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 7 Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 8 North America Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 9 North America Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 10 North America Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 11 North America Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 12 US Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 13 US Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 14 US Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 15 US Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 16 Canada Dravet Syndrome market by Diagnosis, 2020 – 2027, (USD Million)

    Table 17 Canada Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 18 Canada Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 19 Canada Dravet Syndrome market by End User, 2020 – 2027, (USD Million)

    Table 20 South America Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 21 South America Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 22 South America Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 23 South America Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 24 Europe Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 25 Europe Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 26 Europe Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 27 Europe Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 29 Western Europe Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 30 Western Europe Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 31 Western Europe Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Dravet Syndrome market by Diagnosis, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Dravet Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Dravet Syndrome market by End User, 2020 – 2027, (USD Million)

    Table 40 The Middle East & Africa Dravet Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 41 The Middle East & Africa Dravet Syndrome Market by Type of Seizures, 2020 – 2027, (USD Million)

    Table 42 The Middle East & Africa Dravet Syndrome Market by Treatment & Management, 2020 – 2027, (USD Million)

    Table 43 The Middle East & Africa Dravet Syndrome market by End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Dravet Syndrome Market

    Figure 3 Segmentation Market Dynamics for Dravet Syndrome Market

    Figure 4 Global Dravet Syndrome market Share, by Diagnosis 2020

    Figure 5 Global Dravet Syndrome market Share, by Type of Seizures 2020

    Figure 6 Global Dravet Syndrome market Share, by Treatment & Management 2020

    Figure 7 Global Dravet Syndrome market Share, by End User, 2020

    Figure 8 Global Dravet Syndrome market Share, by Region, 2020

    Figure 9 North America Dravet Syndrome market Share, by Country, 2020

    Figure 10 Europe Dravet Syndrome market Share, by Country, 2020

    Figure 11 Asia Pacific Dravet Syndrome market Share, by Country, 2020

    Figure 12 Middle East & Africa Dravet Syndrome market Share, by Country, 2020

    Figure 13 Global Dravet Syndrome market: Company Share Analysis, 2020 (%)

    Figure 14 Biocodex: Key Financials

    Figure 15 Biocodex: Segmental Revenue

    Figure 16 Biocodex: Geographical Revenue

    Figure 17 Biscayne Neurotherapeutics: Key Financials

    Figure 18 Biscayne Neurotherapeutics: Segmental Revenue

    Figure 19 Biscayne Neurotherapeutics: Geographical Revenue

    Figure 20 GW Pharmaceuticals, plc: Key Financials

    Figure 21 GW Pharmaceuticals, plc: Segmental Revenue

    Figure 22 GW Pharmaceuticals, plc: Geographical Revenue

    Figure 23 Zogenix, Inc: Key Financials

    Figure 24 Zogenix, Inc: Segmental Revenue

    Figure 25 Zogenix, Inc: Geographical Revenue

    Figure 26 TAKEDA PHARMACEUTICAL COMPANY LIMITED: Key Financials

    Figure 27 TAKEDA PHARMACEUTICAL COMPANY LIMITED: Segmental Revenue

    Figure 28 TAKEDA PHARMACEUTICAL COMPANY LIMITED: Geographical Revenue

    Figure 29 OPKO HEALTH INC.: Key Financials

    Figure 30 OPKO HEALTH INC.: Segmental Revenue

    Figure 31 OPKO HEALTH INC.: Geographical Revenue

    Figure 32 PTC Therapeutics: Key Financials

    Figure 33 PTC Therapeutics: Segmental Revenue

    Figure 34 PTC Therapeutics: Geographical Revenue